Programs

Phi Pharma's initial focus in on innovative peptide drug conjugates against multiple myeloma, acute myeloid leukaemia and other B-Cell derived malignancies. In parallel, peptide drug conjugates against solid tumours such as ovarian and colorectal cancer have been investigated. Programmes are in in-vivo Proof of Concept and lead-selection/optimisation phase. An adoptive transfer mouse model of a leukaemia cell line has provided proof of concept for the AML programme.